Delaware | 1-10235 | 36-3555336 | ||
(State of | (Commission File Number) | (IRS Employer | ||
Incorporation) | Identification No.) |
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
(d) | Exhibits |
99.1
|
Press release dated July 20, 2011 announcing IDEX Corporations quarterly operating results |
IDEX CORPORATION | ||||
By: | /s/ Heath A. Mitts
|
|||
Vice President and Chief Financial Officer | ||||
July 21, 2011 |
Exhibit | ||
Number | Description | |
99.1
|
Press release dated July 20, 2011 announcing IDEX Corporations quarterly operating results |
| Orders increased 19 percent compared to the prior year (+8 percent organic, +7 percent acquisitions and +4 percent foreign currency translation). |
| Sales increased 20 percent compared to the prior year (+8 percent organic, +8 percent acquisitions and +4 percent foreign currency translation). |
| Operating margin for the second quarter was up 90 basis points on a reported basis and up 130 basis points on an adjusted basis. |
| Reported net income of $50 million was $10 million, or 24 percent, higher than the prior year reported net income. |
| Reported EPS of 60 cents was 11 cents, or 22 percent, higher than the prior year reported EPS. |
| Adjusted EPS of 62 cents was 12 cents, or 24 percent, higher than the prior year adjusted EPS. |
| EBITDA of $97 million was 21 percent of sales and covered interest expense by more than 14 times. |
| Free cash flow was $46 million. |
| Sales in the second quarter of $205 million reflected a 22 percent increase compared to the second quarter of 2010 (+16 percent organic, +2 percent acquisitions and +4 percent foreign currency translation). | ||
| Operating margin of 19.6 percent represented a 180 basis point improvement compared to the second quarter 2010 adjusted operating margin. The improvement in operating margin was primarily related to higher volumes and productivity. |
| Sales in the second quarter of $144 million reflected a 36 percent increase compared to the second quarter of 2010 (+10 percent organic, +23 percent acquisitions and +3 percent foreign currency translation). | ||
| Operating margin adjusted for the $3 million non-cash acquisition fair value inventory charge associated with the CVI Melles Griot acquisition was 21.6 percent representing a 130 basis point increase compared to the second quarter 2010 adjusted operating margin. The improvement in the 2011 adjusted operating margin was the result of higher volumes and productivity. |
| Sales in the second quarter of $36 million reflected a 12 percent decrease compared to the second quarter of 2010 (-21 percent organic and +9 percent for foreign currency translation) due to the prior year North American replenishment program. | ||
| Operating margin of 28.7 percent represented a 510 basis point improvement compared to the second quarter of 2010 operating margin, primarily due to a $2.8 million gain from the sale of a facility in Italy. |
| Sales in the second quarter of $69 million reflected an 8 percent increase compared to the second quarter of 2010 (+3 percent organic and +5 percent for foreign currency translation). | ||
| Operating margin of 23.9 percent represented a 200 basis point improvement compared to the second quarter 2010 adjusted operating margin. The improvement in operating margin was primarily related to favorable product mix. |
For the Quarter Ended | ||||||||||||||||||||
June 30, | March 31, | |||||||||||||||||||
2011 | 2010 | Change | 2011 | Change | ||||||||||||||||
Income before Taxes |
$ | 73.3 | $ | 59.4 | 23 | % | $ | 70.4 | 4 | % | ||||||||||
Depreciation and
Amortization |
17.0 | 15.4 | 10 | 15.6 | 9 | |||||||||||||||
Interest |
6.7 | 3.6 | 87 | 6.4 | 4 | |||||||||||||||
EBITDA |
$ | 97.0 | $ | 78.4 | 24 | $ | 92.4 | 5 | ||||||||||||
Cash Flow from Operating
Activities |
$ | 51.7 | $ | 68.6 | (25) | % | $ | 29.1 | 78 | % | ||||||||||
Capital Expenditures |
(7.2 | ) | (10.0 | ) | (28 | ) | (11.4 | ) | (37 | ) | ||||||||||
Excess Tax Benefit from
Stock-Based Compensation |
1.6 | 1.7 | (5 | ) | 2.4 | (31 | ) | |||||||||||||
Free Cash Flow |
$ | 46.1 | $ | 60.3 | (23 | ) | $ | 20.1 | n/m | |||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net sales |
$ | 453,798 | $ | 378,526 | $ | 880,887 | $ | 734,124 | ||||||||
Cost of sales |
268,959 | 223,705 | 517,348 | 431,762 | ||||||||||||
Gross profit |
184,839 | 154,821 | 363,539 | 302,362 | ||||||||||||
Selling, general and administrative expenses |
105,210 | 91,010 | 206,189 | 178,791 | ||||||||||||
Restructuring expenses |
| 1,031 | | 2,898 | ||||||||||||
Operating income |
79,629 | 62,780 | 157,350 | 120,673 | ||||||||||||
Other income (expense) net |
347 | 239 | (560 | ) | 493 | |||||||||||
Interest expense |
6,720 | 3,599 | 13,174 | 7,033 | ||||||||||||
Income before income taxes |
73,256 | 59,420 | 143,616 | 114,133 | ||||||||||||
Provision for income taxes |
23,074 | 19,022 | 45,483 | 37,110 | ||||||||||||
Net income |
$ | 50,182 | $ | 40,398 | $ | 98,133 | $ | 77,023 | ||||||||
Earnings per Common Share: |
||||||||||||||||
Basic earnings per common share (a) |
$ | 0.61 | $ | 0.50 | $ | 1.19 | $ | 0.95 | ||||||||
Diluted earnings per common share (a) |
$ | 0.60 | $ | 0.49 | $ | 1.17 | $ | 0.94 | ||||||||
Share Data: |
||||||||||||||||
Basic weighted average common shares outstanding |
82,151 | 80,369 | 81,790 | 80,225 | ||||||||||||
Diluted weighted average common shares outstanding |
83,778 | 81,800 | 83,507 | 81,655 |
June 30, | December 31, | |||||||
2011 | 2010 | |||||||
Assets |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ | 202,961 | $ | 235,136 | ||||
Receivables net |
270,234 | 213,553 | ||||||
Inventories |
282,381 | 196,546 | ||||||
Other current assets |
58,429 | 47,523 | ||||||
Total current assets |
814,005 | 692,758 | ||||||
Property, plant and equipment net |
231,538 | 188,562 | ||||||
Goodwill and intangible assets |
1,857,328 | 1,488,393 | ||||||
Other noncurrent assets |
20,449 | 11,982 | ||||||
Total assets |
$ | 2,923,320 | $ | 2,381,695 | ||||
Liabilities and shareholders equity |
||||||||
Current liabilities |
||||||||
Trade accounts payable |
$ | 128,117 | $ | 104,055 | ||||
Accrued expenses |
122,894 | 117,879 | ||||||
Short-term borrowings |
85,020 | 119,445 | ||||||
Dividends payable |
14,095 | 12,289 | ||||||
Total current liabilities |
350,126 | 353,668 | ||||||
Long-term borrowings |
793,117 | 408,450 | ||||||
Other noncurrent liabilities |
269,215 | 243,917 | ||||||
Total liabilities |
1,412,458 | 1,006,035 | ||||||
Shareholders equity |
1,510,862 | 1,375,660 | ||||||
Total liabilities and shareholders equity |
$ | 2,923,320 | $ | 2,381,695 | ||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 (b) | 2010 (c) | 2011 (b) | 2010 (c) | |||||||||||||
Fluid & Metering Technologies |
||||||||||||||||
Net sales |
$ | 205,251 | $ | 168,803 | $ | 400,524 | $ | 335,911 | ||||||||
Operating income (d) |
40,288 | 30,005 | 80,525 | 61,365 | ||||||||||||
Operating margin |
19.6 | % | 17.8 | % | 20.1 | % | 18.3 | % | ||||||||
Depreciation and amortization |
$ | 8,211 | $ | 7,906 | $ | 16,180 | $ | 15,632 | ||||||||
Capital expenditures |
3,040 | 6,037 | 6,507 | 9,631 | ||||||||||||
Health & Science Technologies |
||||||||||||||||
Net sales |
$ | 144,119 | $ | 106,231 | $ | 277,754 | $ | 199,522 | ||||||||
Operating income (d) (e) |
31,065 | 21,546 | 62,179 | 41,812 | ||||||||||||
Operating margin |
21.6 | % | 20.3 | % | 22.4 | % | 21.0 | % | ||||||||
Depreciation and amortization |
$ | 6,019 | $ | 4,661 | $ | 11,032 | $ | 8,472 | ||||||||
Capital expenditures |
1,984 | 2,326 | 5,323 | 3,804 | ||||||||||||
Dispensing Equipment |
||||||||||||||||
Net sales |
$ | 36,146 | $ | 41,135 | $ | 68,304 | $ | 74,689 | ||||||||
Operating income (d) |
10,377 | 9,716 | 16,016 | 16,470 | ||||||||||||
Operating margin |
28.7 | % | 23.6 | % | 23.4 | % | 22.1 | % | ||||||||
Depreciation and amortization |
$ | 901 | $ | 1,131 | $ | 1,924 | $ | 2,164 | ||||||||
Capital expenditures |
426 | 459 | 850 | 642 | ||||||||||||
Fire & Safety/Diversified Products |
||||||||||||||||
Net sales |
$ | 69,046 | $ | 63,991 | $ | 135,775 | $ | 127,392 | ||||||||
Operating income (d) |
16,488 | 14,041 | 31,991 | 27,464 | ||||||||||||
Operating margin |
23.9 | % | 21.9 | % | 23.6 | % | 21.6 | % | ||||||||
Depreciation and amortization |
$ | 1,474 | $ | 1,346 | $ | 2,793 | $ | 2,798 | ||||||||
Capital expenditures |
951 | 1,012 | 2,211 | 1,876 | ||||||||||||
Company |
||||||||||||||||
Net sales |
$ | 453,798 | $ | 378,526 | $ | 880,887 | $ | 734,124 | ||||||||
Operating income (f) |
82,629 | 63,811 | 160,350 | 123,571 | ||||||||||||
Operating margin |
18.2 | % | 16.9 | % | 18.2 | % | 16.8 | % | ||||||||
Depreciation and amortization (g) |
$ | 16,954 | $ | 15,369 | $ | 32,576 | $ | 29,653 | ||||||||
Capital expenditures |
7,004 | 10,686 | 17,088 | 18,036 |
(a) | Calculated by applying the two-class method of allocating earnings to common stock and participating securities as required by ASC 260, Earnings Per Share. | |
(b) | Three month and six month data includes acquisitions of OBL (July 2010) in the Fluid & Metering Technologies segment and CVI (June 2011), Microfluidics (March 2011), Advanced Thin Films (January 2011), Fitzpatrick (November 2010) and Seals-PPE (April 2010) in the Health & Science Technologies segment from the date of acquisition. | |
(c) | Financial data has been revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies segment to the Health & Science Technologies segment. | |
(d) | Group operating income excludes unallocated corporate operating expenses and 2010 restructuring-related charges. | |
(e) | Operating income within the Health & Science Technologies segment excludes the $3.0 million CVI Melles Griot non-cash acquisition fair value inventory charge in the second quarter of 2011. | |
(f) | Company operating income for the three and six month periods of 2011 excludes the $3.0 million CVI Melles Griot non-cash acquisition fair value inventory charge. Company operating income for the three and six month periods of 2010 excludes $1.0 million and $2.9 million, respectively, of restructuring-related charges. | |
(g) | Excludes amortization of debt issuance expenses. |